Office Headquarters: (610) 544-3500

perirx log in button

PeriRx Logo


Get News and Updates



CLIA: 39D2085645

PeriRx on Facebook PeriRx on YouTube PeriRx on Google+ Stephen M. Swanick LinkedIn


New York State has a separate and unique regulatory approval process for laboratory diagnostic testing. PeriRx is currently in the application process with our SaliMark™ OSCC test and is vigorously committed to pursuing this application approval. 

Future Pipeline Products

SaliMark™ is the product line of advanced molecular DNA tests commercialized by PeriRx. These salivary tests are based on a strong scientific foundation of NIH-funded research with initial discovery and pre-validation work by Dr. David Wong of UCLA.

This product portfolio pipeline is at various stages of pre-commercialization. Our breakthrough genetic testing technology affords us the opportunity to develop the future tests listed below as well as many additional ones not disclosed.

SaliMark™ LC is an early detection lung cancer-screening test. Patient enrollment has already begun for the landmark, groundbreaking clinical trial.

SaliMark™ SS is an early detection Sjögren’s Syndrome screening test. Sjögren’s Syndrome is a systemic chronic inflammatory disorder. For more information, please read Prospects for Genetic Intervention in Salivary Glands of  Sjögren’s Patients.

SaliMark™ D2 is for the early detection of pre-diabetes and type II diabetes.

PeriRx is committed to the ongoing development of breakthrough, non-invasive, oral diagnostic technology to help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.

Working in the laboratory